Adocia signs an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors

- Preclinical results have already demonstrated its remarkable action on solid tumors
- A first proprietary product is under development to treat ovarian cancer
- This platform can be used with a wide range of anti-tumoral agents

Lyon, December 9, 2013 - Adocia (Euronext Paris: FR0011184241 - ADOC), a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert (SATT Aquitaine). This agreement grants Adocia with development and commercialization rights over an international patent application protecting a nanotechnology for drug delivery in the field of healthcare. The cash position of the company is not significantly impacted by this acquisition, for which financial terms remain confidential.

While pursuing as scheduled the clinical studies plan on its three insulin products and on its product for chronic wound healing, Adocia has taken the opportunity to develop a new technology for oncology. Its scientific expertise in drug delivery will be crucial for rapid industrial development.

This new technology, called DriveIn® was developed by Professor Sébastien Lecommandoux and his team at the Laboratoire de Chimie des Polymères Organiques (LCPO, UMR5629 CNRS - Université de Bordeaux I – Institut polytechnique de Bordeaux). It is remarkably efficient in carrying active molecules and delivering them within solid tumors. This work has been published in multiple peer-reviewed journals.

Adocia will adopt a dual strategy for the development of this technology. On the one hand, Adocia intends to develop proprietary products based on doxorubicin and docetaxel, two of the most used anti-tumoral treatments, which could greatly benefit from an enhanced intra-cellular delivery. On the other hand, Adocia will propose the DriveIn technology to pharmaceutical companies to optimize the efficacy of their own proprietary molecules.
Research is ongoing to develop new treatments in oncology, but also to improve the performance of commercial products while limiting their side effects. Today, one of the main challenges is to more efficiently target the molecules towards solid tumors, so as to concentrate them on cancer cells and limit the damage to healthy tissues.

The originality of DriveIn consists in using nanoparticles that have a surface completely made of hyaluronan, a biopolymer naturally present in the human body, known to interact with the CD44 cell receptor. This receptor is overexpressed in a large number of solid tumors, thus allowing DriveIn nanoparticles to efficiently reach and penetrate cancer cells, which is known to be a limitation of current therapies.

“The remarkable ability of DriveIn nanoparticles to diffuse throughout the tumor and get actively internalized by cancer cells has convinced us of the uniqueness of this technology,” said Olivier Soula, Director of Research and Development at Adocia. “Our primary objective is to develop a proprietary formulation for treating ovarian cancer and to launch the first clinical trial in Q4 2014.”

“We are very happy with this acquisition now that the products based on the BioChaperone technology are in clinical development,” said Gérard Soula, Adocia’s CEO. Considering our team’s expertise, this new platform in nanotechnology for applications is an exceptional opportunity to fight cancer by improving the efficacy of already approved treatments”

Next scheduled events
Adocia will attend ODDO Midcap Forum, Lyon, France – January 9th and 10th, 2014.

About Adocia:
"Innovative medicine for everyone, everywhere"
Adocia is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins. Adocia is specialized in insulin therapy and the treatment of the diabetic foot, one of the main complications of diabetes. Worldwide, more than 366 million individuals are currently suffering from diabetes (with a forecast of 552 million individuals by 2030, i.e. a 51% increase, reaching 70% in emerging countries). 15% of these patients will develop a foot ulcer during their lifetime. The markets targeted by Adocia represent more than USD20 billion (USD17 billion for insulin therapy and USD3 billion for diabetic foot ulcer healing).

Through its BioChaperone® state-of-the-art technological platform, Adocia intends to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public.

Adocia successfully completed two phases I and II studies on the formulation of a fast-acting human insulin and obtained promising phase I/II results on a diabetic foot ulcer-healing product. Furthermore, Adocia is developing a unique combination of fast-acting insulin and slow-acting insulin, for an optimal insulin therapy with one single product.

To be a global leader for the formulation of therapeutic proteins
Based on its experience and recognized know-how, Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of numerous chronic pathologies (oncology, inflammation, etc.). In this field, Adocia is engaged in collaborative programs with two major pharmaceutical companies.
Adocia’s therapeutic innovations aim at bringing solutions to a profoundly changing global pharmaceutical and economic context, characterized in particular by the increased prevalence and
impact of the targeted pathologies, population growth and ageing, the need to control public health expenditures and increasing demand from emerging countries.

Adocia is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241, mnemo / Reuters / Bloomberg: ADOC, ADOC.PA, ADOC.FP) and its share included in the Next Biotech index. For more information: www.adocia.com

Contact
Gérard Soula - contactinvestisseurs@adocia.com
Chairman and CEO of Adocia
Tél. : +33 4 72 610 610

Press Relations
Andrew Lloyd & Associates
Juliette dos Santos / Sandra Régnavaque
juliette@ala.com – sandra@ala.com
Tél. : +33 1 56 54 07 00

Financial communication & Investor Relations
NewCap
Pierre Laurent / Julien Perez - adocia@newcap.fr
Tél. : +33 1 44 71 94 94

Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the "Risk Factors" section of the Reference Document registered by the Autorité des marchés financiers on April 25, 2013 under number R13-017 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.